Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jul 21, 2009; 15(27): 3426-3430
Published online Jul 21, 2009. doi: 10.3748/wjg.15.3426
Published online Jul 21, 2009. doi: 10.3748/wjg.15.3426
Figure 1 Postoperative clinical course of patient 1.
Tac: Tacrolimus; MMF: Mycophenolate mofetil; RATG: Rabbit anti-thymocyte globulins; MARS: Molecular adsorbents recirculating system; LB: Liver biopsy; PP: Plasmapheresis; R: Rituximab; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma glutamyl transpeptidase.
Figure 2 Postoperative clinical course of patient 2.
Figure 3 Liver biopsies performed in patient 2.
A: Liver biopsy performed on day 10. Acute rejection with mixed inflammatory cells in the portal triad, significant cholangitis and endothelitis. Banff activity index of 7 (HE, × 400); B: Immunostaining with L26 antibody (anti-CD20) showed moderate proportion of B cells (× 400); C: Liver biopsy performed on day 10: Immunostaining for C4d in liver biopsy (× 400); D: Liver biopsy performed at 3 mo post-transplant showed complete resolution of acute rejection (HE, × 400); E: Immunostaining with L26 antibody (anti-CD20) showed no B cell infiltration (× 400).
- Citation: Kamar N, Lavayssière L, Muscari F, Selves J, Guilbeau-Frugier C, Cardeau I, Esposito L, Cointault O, Nogier MB, Peron JM, Otal P, Fort M, Rostaing L. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15(27): 3426-3430
- URL: https://www.wjgnet.com/1007-9327/full/v15/i27/3426.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.3426